Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

NCT02378935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: VOX
DRUG: SOF/VEL
DRUG: RBV

Sponsor

Gilead Sciences